A transgenic alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric Aβ, and frank neuronal loss

Journal of Neuroscience

Volumn 33, Issue 15, 2013, Pages 6245-6256

  Cohen, Robert M ^a,f,i   Rezai Zadeh, Kavon ^a   Weitz, Tara M ^a   Rentsendorj, Altan ^a   Gate, David ^a   Spivak, Inna ^a   Bholat, Yasmin ^a   Vasilevko, Vitaly ^b   Glabe, Charles G ^b   Breunig, Joshua J ^a   Rakic, Pasko ^c   Davtyan, Hayk ^b,d   Agadjanyan, Michael G ^b,d   Kepe, Vladimir ^f   Barrio, Jorge R ^f   Bannykh, Serguei ^a,f   Szekely, Christine A ^a   Pechnick, Robert N ^a,e,h   Town, Terrence ^a,f,g  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BARNES DEVICE; BEHAVIOR DISORDER; BRAIN CORTEX; CHEMICAL ANALYSIS; COGNITION; CONTROLLED STUDY; DISEASE COURSE; GENOTYPE; GLIOSIS; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MICROSCOPY; NERVE DEGENERATION; NONHUMAN; OPEN FIELD TEST; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; RECOGNITION; SENILE PLAQUE; STEREOLOGY; TAUOPATHY; TRANSGENIC RAT;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL CORTEX; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; GLIOSIS; HIPPOCAMPUS; HUMANS; MALE; NERVE DEGENERATION; PLAQUE, AMYLOID; PRESENILIN-1; RATS; RATS, INBRED F344; RATS, TRANSGENIC; TAU PROTEINS; TAUOPATHIES;

EID: 84875975993     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3672-12.2013     Document Type: Article

References (64)

1. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 21:RC189.
2. Barnes CA (1979) Memory deficits associated with senescence: a neuro-physiological and behavioral study in the rat. J Comp Physiol Psychol 93:74-104.
3. Barnes CA, Jung MW, McNaughton BL, Korol DL, Andreasson K, Worley PF (1994) LTP saturation and spatial learning disruption: effects of task variables and saturation levels. J Neurosci 14:5793-5806.
4. Behl C (2000) Apoptosis and Alzheimer's disease. J Neural Transm 107: 1325-1344.
5. Braak H, Braak E (1990) Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49:215-224.
6. Braak H, Braak E, Bohl J, Lang W (1989) Alzheimer's disease: amyloid plaques in the cerebellum. J Neurol Sci 93:277-287.
7. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-PierratC,Staufenbiel M, SommerB,Jucker M (1998) Neuron loss in APP transgenic mice. Nature 395:755-756.
8. Colton CA, Wilcock DM, Wink DA, Davis J, Van Nostrand WE, Vitek MP (2008) The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis 15:571-587.
9. Cotman CW, Anderson AJ (1995) A potential role for apoptosis in neuro-degeneration and Alzheimer's disease. Mol Neurobiol 10:19-45.
10. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464:1201-1204.
11. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP (2002) Nonoverlapping but synergetic tau and APP pathologiesinsporadic Alzheimer's disease. Neurology 59:398-407.
12. Dickson DW, Wertkin A, Mattiace LA, Fier E, Kress Y, Davies P, Yen SH (1990) Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol 79: 486-493.
13. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Pereztur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 383:710-713.
14. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A (1996) Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Neurology 46: 1592-1596.
15. Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M (2012) First transgenic rat model developing progressive cortical neurofibrillary tangles. Neurobiol Aging 33:1448-1456.
16. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717f beta-amyloid precursor protein. Nature 373:523-527.
17. Gorman AM (2008) Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. J Cell Mol Med 12:2263-2280.
18. Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteinsby polyacrylamide gel electro-phoresis. Proc Natl Acad Sci U S A 87:5827-5831.
19. Hanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M (2009) Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. J Neurochem 108:1167-1176.
20. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12:383-388.
21. Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
22. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
23. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925-931.
24. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gütz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142:387-397.
25. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157-165.
26. Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135:309- 319.
27. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McCo-nlogue L (1997) Amyloid precursor protein processing and a-beta(42) deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94:1550-1555.
28. Kayed R, Glabe CG (2006) Conformation-dependent anti-amyloid oli-gomer antibodies. Methods Enzymol 413:326-344.
29. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489.
30. Lamy C, Duyckaerts C, Delaere P, Payan C, Fermanian J, Poulain V, Hauw JJ (1989) Comparison of seven staining methods for senile plaques and neurofibrillary tangles in a prospective series of 15 elderly patients. Neu-ropathol Appl Neurobiol 15:563-578.
31. Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE (2007) Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hip-pocampal Abeta levels. Mol Neurodegener 2:11.
32. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercau-teren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC (2010) A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 20:113-126.
33. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K (2008) A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis 31:46-57.
34. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862.
35. McMillan P, Korvatska E, Poorkaj P, Evstafjeva Z, Robinson L, Greenup L, Leverenz J, Schellenberg GD, D'Souza I (2008) Tau isoform regulation is region- and cell-specific in mouse brain. J Comp Neurol 511:788-803.
36. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20:4050-4058.
37. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG (2007) Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 46:8850-8860.
38. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneu-ronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129-10140.
39. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Mether-ate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic modelof Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409-421.
40. Padmanabhan J, Levy M, Dickson DW, Potter H (2006) Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 129:3020-3034.
41. Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates. San Diego: Academic.
42. Rebeck GW, Hoe HS, Moussa CE (2010) Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem 285:7440-7446.
43. Rosenwald A, Reusche E, Ogomori K, Teichert HM (1993) Comparison of silver stainings and immunohistology for the detection of neurofibrillary tangles and extracellular cerebral amyloid in paraffin sections. Acta Neu-ropathol 86:182-186.
44. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL (1989) A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 48:674-691.
45. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
46. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837-842.
47. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663.
48. Stadelmann C, Brück W, Bancher C, Jellinger K, Lassmann H (1998) Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 57:456-464.
49. Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol 65:906-912.
50. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Roth-acher S, Ledermann B, Burki K, Frey P, Paganetti PA, Bürki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94:13287-13292.
51. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW (2001) Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res 898:350-357.
52. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286:2352-2355.
53. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5:1288-1293.
54. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14:681-687.
55. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oli-gomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39:10831-10839.
56. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002a) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation invivo. Nature 416:535-539.
57. Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ (2002b) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30:552-557.
58. Wan H, Aggleton JP, Brown MW (1999) Different contributions of the hippocampus and perirhinal cortex to recognition memory. J Neurosci 19: 1142-1148.
59. Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Ghark-holonarehe N, Vitek MP, Colton CA (2008) Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J Neurosci 28:1537-1545.
60. Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L (1997) Amyloidogenic role of cytokine TGF-beta1 in trans-genic mice and in Alzheimer's disease. Nature 389:603-606.
61. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L (2001) TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 7:612-618.
62. Yang S, Smit AF, Schwartz S, Chiaromonte F, Roskin KM, Haussler D, Miller W, Hardison RC (2004) Patterns of insertions and their covariation with substitutions in the rat, mouse, and human genomes. Genome Res 14:517-527.
63. Yoshiike Y, Minai R, Matsuo Y, Chen YR, Kimura T, Takashima A (2008) Amyloid oligomer conformation in a group of natively folded proteins. PLoS One 3:e3235.
64. Zhu X, Raina AK, Perry G, Smith MA (2006) Apoptosis in Alzheimer disease: a mathematical improbability. Curr Alzheimer Res 3:393-396.